Extracorporeal Life Support Organization Registry International Report 2022: 100,000 Survivors.

Autor:	Tonna JE; From the Division of Cardiothoracic Surgery, Department of Surgery, University of Utah Health, Salt Lake City, Utah.; Department of Emergency Medicine, University of Utah Health, Salt Lake City, Utah., Boonstra PS; Department of Biostatistics, University of Michigan, Ann Arbor, Michigan., MacLaren G; Cardiothoracic Intensive Care Unit, National University Hospital, Singapore, Singapore., Paden M; Department of Surgery, Division of Pediatric Critical Care Medicine, Emory University School of Medicine, Atlanta, Georgia., Brodie D; Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland., Anders M; Department of Surgery, Division of Critical Care, Texas Children's Hospital, Baylor College of Medicine, Houston, Texas., Hoskote A; Department of Surgery, Heart and Lung Directorate, Great Ormond Street Hospital for Children NHS Foundation Trust, London, UK.; Department of Surgery, Institute of Cardiovascular Science, University College London, Zayed Centre for Research into Rare Diseases in Children, London, UK., Ramanathan K; Department of Surgery, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.; Department of Surgery, Cardiothoracic Intensive Care Unit, National University Heart Centre, National University Hospital, Singapore, Singapore., Hyslop R; Department of Surgery, Heart Institute, Children's Hospital Colorado, Aurora, Colorado., Fanning JJ; Department of Pediatrics, Extracorporeal Life Support Program, Medical City Children's Hospital, Dallas, Texas., Rycus P; Department of Surgery, Extracorporeal Life Support Organization (ELSO), Ann Arbor, Michigan., Stead C; Department of Surgery, Extracorporeal Life Support Organization (ELSO), University of Michigan, Ann Arbor, Michigan., Barrett NA; Department of Critical Care, Guy's and St Thomas' NHS Foundation Trust, London, UK.; Department of Surgery, Centre for Human & Applied Physiological Sciences, King's College London, London, UK., Mueller T; Intensive Care Medicine, Department of Internal Medicine II, University Hospital Regensburg, Germany., Gómez RD; Department of Surgery, Terapias Avanzadas de Soporte Cardiopulmonar, Hospitales Tec Salud, Escuela de Medicina ITESM, Monterrey, Mexico., Malhotra Kapoor P; Department of Cardiac Anaesthesiology and Critical Care, Cardio Thoracic Centre, All India Institute of Medical Sciences (AIIMS), New Delhi, India., Fraser JF; Department of Surgery, University of Queensland, The Prince Charles Hospital, Brisbane, Australia., Bartlett RH; Department of Surgery, University of Michigan, Ann Arbor, Michigan., Alexander PMA; Department of Cardiology, Boston Children's Hospital, Boston, Massachusetts.; Department of Pediatrics, Harvard Medical School, Boston, Massachusetts., Barbaro RP; Division of Critical Care Medicine, Department of Pediatrics, University of Michigan, Ann Arbor, Michigan.; Department of Surgery, Susan B. Meister Child Health Evaluation and Research Center, University of Michigan, Ann Arbor, Michigan.
Jazyk:	angličtina
Zdroj:	ASAIO journal (American Society for Artificial Internal Organs : 1992) [ASAIO J] 2024 Feb 01; Vol. 70 (2), pp. 131-143. Date of Electronic Publication: 2024 Jan 05.
DOI:	10.1097/MAT.0000000000002128
Abstrakt:	The Extracorporeal Life Support Organization (ELSO) maintains the world's largest extracorporeal membrane oxygenation (ECMO) registry by volume, center participation, and international scope. This 2022 ELSO Registry Report describes the program characteristics of ECMO centers, processes of ECMO care, and reported outcomes. Neonates (0-28 days), children (29 days-17 years), and adults (≥18 years) supported with ECMO from 2009 through 2022 and reported to the ELSO Registry were included. This report describes adjunctive therapies, support modes, treatments, complications, and survival outcomes. Data are presented descriptively as counts and percent or median and interquartile range (IQR) by year, group, or level. Missing values were excluded before calculating descriptive statistics. Complications are reported per 1,000 ECMO hours. From 2009 to 2022, 154,568 ECMO runs were entered into the ELSO Registry. Seven hundred and eighty centers submitted data during this time (557 in 2022). Since 2009, the median annual number of adult ECMO runs per center per year increased from 4 to 15, whereas for pediatric and neonatal runs, the rate decreased from 12 to 7. Over 50% of patients were transferred to the reporting ECMO center; 20% of these patients were transported with ECMO. The use of prone positioning before respiratory ECMO increased from 15% (2019) to 44% (2021) for adults during the coronavirus disease-2019 (COVID-19) pandemic. Survival to hospital discharge was greatest at 68.5% for neonatal respiratory support and lowest at 29.5% for ECPR delivered to adults. By 2022, the Registry had enrolled its 200,000th ECMO patient and 100,000th patient discharged alive. Since its inception, the ELSO Registry has helped centers measure and compare outcomes across its member centers and strategies of care. Continued growth and development of the Registry will aim to bolster its utility to patients and centers. Competing Interests: Disclosure: J.E.T. is the Chair of the Registry Committee of the Extracorporeal Life Support Organization (ELSO). P.S.B. receives salary support from ELSO. G.M. is the President of ELSO. M.P. is the Immediate past President of ELSO. D.B. receives research support from and consults for LivaNova. He has been on the medical advisory boards for Abiomed, Xenios, Medtronic, Inspira, and Cellenkos. He is the President-elect of ELSO and the Chair of the Executive Committee of the International ECMO Network (ECMONet), and he writes for UpToDate. M.A., A.H., and K.R. are the Immediate Past Co-Chairs of the Scientific Oversight Committee of ELSO. P.R. is the Executive Director of ELSO. C.S. is the Chief Executive Officer (CEO) of ELSO. N.A.B. is the President of European Chapter of ELSO. N.A.B. has been on the medical advisory boards for Xenios and Baxter. T.M. is on the Board of Directors of ELSO. R.D.G. is the President of the Latin-American Chapter of ELSO. P.M.K. is the President of the South West Asia and Africa Chapter of ELSO. J.F.F. is the President of Asia-Pacific Chapter of ELSO. P.M.A.A. is Treasurer of ELSO Board of Directors. P.M.A.A. is funded by U.S. DoD PRMRP Clinical Trial Award #W81XWH2210301, NIH (R13HD104432) and FDA UCSF-Stanford Center of Excellence in Regulatory Sciences and Innovation (U01FD004979/U01FD005978). None of the funding sources were involved in the design or conduct of the study, collection, management, analysis, or interpretation of the data, or preparation, review, or approval of the manuscript. No other conflicts of interest reported. R.P.B. is a member of the Board of Directors for ELSO and receives funding from the National Heart, Lung, And Blood Institute (R01 HL153519). (Copyright © ASAIO 2024.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu